How did Eli Lilly's revenue and expenses trend in Q4 2024?

Eli Lilly's revenue and expenses in Q4 2024 are not currently available. However, we can analyze the trends leading up to this quarter.

1. Revenue Trend: Lilly's revenue has shown a significant increase in Q3 2024, with a 42% growth driven by drugs Mounjaro and Zepbound. The company raised its 2024 revenue guidance to $45.4 billion to $46 billion, indicating confidence in continued growth.
2. Expense Trend: The company's expenses, including research and development and marketing, selling, and administrative costs, have increased in Q3 2024. This is likely due to the higher sales and strategic investments in pipeline developments and manufacturing.

Overall, Eli Lilly's revenue has demonstrated robust growth, while expenses have risen in line with the company's strategic investments and operational activities. The trends suggest that the company is performing well, despite some challenges in inventory management and expectations adjustments.